Q-Line Biotech Ltd IPO
Trading
Price Band
₹326 – ₹343
Lot Size
400
Minimum Bid Quantity
800
Minimum Investment
₹274400
Issue Size
₹214.48Cr
Opens
2026-05-21
Closes
2026-05-25
Listing
29-05-2026
Subscription Status
Qualified Institutional Buyers
109.34 x
Non-Institutional Investor
105.25 x
Retail Individual Investor
66.41 x
Total
88.28 x
IPO Details
Issue Type
EQUITY
Face Value
₹10
Tick Size
1
ISIN
INE1G2W01011
Pre-Apply Available
No
Daily Bidding Time
10:00:00 - 17:00:00
About the Company
Q-Line Biotech Limited is engaged in the development, manufacturing, and marketing of diagnostic reagents, consumables, and in-vitro diagnostic (IVD) equipment for healthcare and diagnostic applications. The company supplies products such as clinical chemistry reagents, haematology and immunodiagnostic products, molecular diagnostic kits, rapid test kits, point-of-care devices, analysers, laboratory consumables, and diagnostic instruments to diagnostic laboratories, hospitals, and medical colleges. It also provides annual maintenance and after-sales services for medical equipment. During the Covid-19 pandemic, the company developed products including RT-PCR kits, RNA extraction kits, and VTM kits. Q-Line Biotech operates multiple manufacturing facilities, warehouses, and offices in Lucknow, Uttar Pradesh, Delhi, Kolkata and Bhubaneswar. Its manufacturing operations include indigenous production of reagents and diagnostic analysers, while some products are manufactured under technical collaborations with international companies.
Pros
- • Q-Line Biotech claims to have established manufacturing and R&D capabilities in the in-vitro diagnostics (IVD) segment. The company operates four manufacturing facilities, including three in Lucknow and one in Delhi, with installed capacity for manufacturing reagent kits and diagnostic analysers. It also claims to have a dedicated R&D team of 19 scientists and engineers working on product development, reverse engineering, and validation.
- • The company has developed a diversified product portfolio across multiple diagnostic categories. Its offerings include clinical chemistry reagents, haematology reagents, rapid and Elisa kits, molecular diagnostic products, diagnostic analysers, consumables, and annual maintenance services for diagnostic equipment. Reagents and diagnostic instruments together contributed a major portion of its revenue in recent financial years.
- • Q-Line Biotech claims to have expanded its manufacturing infrastructure through additional facilities commissioned in 2026. According to the prospectus, the expansion is expected to increase production capacity for clinical chemistry reagents, Rapid/Elisa kits, glucometer devices, and glucometer strips. The company is also developing and manufacturing certain “Make in India” diagnostic analysers and laboratory devices.
Cons
- • The company’s business is significantly dependent on its distributor network, including group entity POCT Services. The top distributor contributed Rs 151.94 crore (65.37%), Rs 197.48 crore (62.94%), Rs 105.22 crore (51.67%), and Rs 69.26 crore (37.90%) to revenue during the period ended December 31, 2025, in FY25, FY24, and FY23, respectively. Further, the top 10 distributors contributed Rs 187.36 crore (80.61%), Rs 257.79 crore (82.16%), Rs 155.03 crore (76.13%), and Rs 138.25 crore (75.66%) during the same periods. Loss of any of these distributors, failure to renew agreements on favourable terms, or the inability to maintain after-sales support may hurt the company’s business operations and financial condition.
- • The company is dependent on a limited number of suppliers for the procurement of raw materials and traded diagnostic instruments. For raw materials, the top three suppliers contributed Rs 10.27 crore (22.57%), Rs 6.56 crore (14.41%), and Rs 4.36 crore (9.59%) of total raw material purchases during the period ended December 31, 2025. In the instruments segment, the top supplier alone contributed Rs 12.65 crore (47.21%), Rs 19.71 crore (57.08%), Rs 39.34 crore (61.70%), and Rs 10.87 crore (30.87%) of instrument purchases in the period ended December 31, 2025, FY25, FY24, and FY23, respectively. Any disruption in supplies, increase in procurement costs, supply shortages, or preferential pricing offered to competitors could adversely affect the company’s operations, profitability, and customer servicing capabilities.
- • The company’s operations are dependent on obtaining, renewing, and maintaining multiple statutory approvals, licenses, registrations, and regulatory clearances across its manufacturing facilities, warehouses, and branch offices. The company has several approvals that are pending, yet to be applied for, or are still held in its previous name, including GST registration, import licences, warehouse licences under the Drugs and Cosmetics Rules, fire safety approvals, trade licences, and R&D recognition certificates. Any delay, suspension, non-renewal, cancellation, or failure to obtain these approvals could result in penalties, regulatory actions, disruption in operations, restrictions on imports, lease termination of certain facilities, or temporary suspension of business activities, which may adversely affect the company’s business and financial condition.
Get real-time IPO alerts on WhatsApp
Opening reminders • Subscription updates • GMP alerts • Allotment results
Start WhatsApp Alerts